Definition 4/4: Maximum Daily Dose
The "CDC Method" ignores dates and days supply for max single-day exposure, used in the CDC Opioid Guideline mobile app.
For reals, does any of this really matter?
Stay tuned: Subtle choices make huge differences.
A Controlled Experiment that mimics an observational policy/intervention evaluation.
Compare 2 places to see which has more "high dose" patients.
Same dataset, same conversion factors.
The ONLY source of variation comes from the4 definitions ofdaily MME.
Methods. PDMP data for 3Q2018.
9,436,640 opioid analgesic prescriptions
California n=5,677,277
Florida n=3,759,363
3,916,461 unique adult residents
California n=2,430,870 (7.9 per 100 residents)
Florida n=1,485,591 (8.7 per 100 residents)
3-fold difference in which patients are considered high dose between D1 and D4. Both are described in published papers as the "CDC Method": 5.9% vs. 14.2% (FL)
Arbitrary definition choice impacts hundreds of thousands of patients with painful conditions.
4 policy/intervention evaluations on the SAME DATA with the SAME CONVERSION TABLES wouldn't agree how many more "high dose" patients were in FL: 64%, 59%, 84%, or 39% more
Any of these means or medians could have been justified scientifically. SAME DATA but 8 different results. See? Subtle choices have huge consequences.
Would we say that doses are similar (1 mg difference) but lots more "high dose" patients in FL?
or
FL has a bit more "high dose" patients, but they are getting A LOT more (13 mg)?
Imma a say it again: Subtle choices have huge consequences in what we infer.
Why is this happening? Overlapping prescription days supply has a lot to do with it.
Epi/stats folks, beware. Changes in US prescribing patterns mean that certain definitions (D1) will attenuate intervention effects over time!
If you shift the “high dose” threshold from 90.9 to 90.0, you increase the number of “high dose” patients by 15.4% (CI: 15.2%, 15.7%).
If an insurance company and physician use 90.0 vs. 90.9, they would disagree on "high dose" status in 1 out of every 30 patients with D4.
Which definition to use? I like D2 in general, but D3 is good for long-term use because it is more robust to misclassification. Do not use D1. If toxicity is short-term in opioid naive patients, D4 could possibly maybe be sorta acceptable.
We are building a tool for research decisions. We need beta testers! DM or email me if you're interested.
"And while everyone debates whether the MME limit was the right thing to do, we are forced to live by it, because medical personnel treat guidelines as mandates. So we wait. And we suffer. And we hope it will all get sorted so we can get the care we need.” Liz Joniak-Grant
Or, as one patient put it to me when I showed them the results: "It's f--king arithmetic. Get it right."
Limitations of our study are here. We don't recommend using these conversion factors naively for clinical decisions, either.
If a study doesn't sufficiently define how they calculated MME per day, I don't read the results.
These results will be published in @ClinJrnlPain (Clinical Journal of Pain) in a couple of weeks. Paper has been accepted and proofs are being typeset one last round. And yes, it'll be free open access. In the meantime, check out OpioidData.org for details.
Thanks to our talented illustrator-in-residence @brittainpeck for breathing visual life into technical medical concepts. Feel free to use any images or slides.
In closing, if you are a researcher, please please please state your definition. Feel free to reuse our equations or slides. In this way, we can be allied with patients to reduce the most harm, with the best information.
We first observed #medetomidine in NC in a sample collected in October 2022, in Raleigh. Combined with xylazine, and traces of fentanyl and meth. @LunaJBear streetsafe.supply/results/p/3004…
If you've seen me present in the last year, #medetomidine has been sitting on our team's Watch List (slide 52) for awhile now. cdr.lib.unc.edu/concern/schola…
1 🚨Attention please: Turns out #xylazine is a kappa opioid. This validates experience from frontline folks and PWUD. Fresh science from collaborators @nanopharmNC @MadiganLBedard @zenbrainest
Pre-print:
Public health 🧵 below
#TwitteRx #harmreductionbiorxiv.org/content/10.110…
Check out @nanopharmNC's explainer on the lab science. I'll breakdown the #publichealth implications.
@nanopharmNC Basic pharmacology. Mu is the opioid receptor in the brain we usually talk about when we say “opioid” – but there are others. Kappa is less popular, but still very much an opioid receptor. HOWEVER, it’s NOT canonically linked to opioid euphoria.
Let's talk #nalmefene for OD reversal, an old generic drug in new expensive clothes. FDA approved Rx-only nasal spray today. Will this help prevent overdose deaths in the fentanyl-xylazine-strongbenzo era?
Nalmefene was developed in the 1980s by erstwhile Key Pharma in Miami, with help from scientists at @UVA europepmc.org/article/med/39…
It was marketed as an injectable by Baxter Pharma as Revex for alcohol dependence, initially approved in April 1995 and "discontinued on May 21, 2008, for business reasons."
2. Most commonly... Fentanyl and #xylazine in combo, about 3:1.
We don't see xylazine-related synthesis impurities but do see fentanyl impurities, so our hypothesis is that xyl is being added intentionally in pure form.
Example from Lexington NC: streetsafe.supply/results/p/3003…
Y'all ready for this? 🍿👊 #NarcanAdCom about to pop off
Use this # to follow today's updates
CONCEPT
The culmination of 2 decades of advocacy to make naloxone OTC
REALITY
2 decades of advocacy erased by overdose crisis profiteers $EBS
Right out the gate, FDA frames this as a solution for saving kids from overdose. Guess that’s why there are so many pediatric anesthesiologists on the AdCom
In the review of the history FDA forgets to credit the people (like Dan Bigg) who invented the intervention
@US_FDA@DrCaliff_FDA listened to harm reduction programs and made it infinitely easier to purchase #naloxone in bulk. With 100,000+ overdose deaths each year, we need BIG solutions.